Non-Hodgkin lymphoma Posts on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

Evaluating BEAM conditioning for allogeneic stem cell transplantation in patients with relapsed or unresponsive lymphoma

Posted by on Jan 17, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of BEAM (carmustine, etoposide, cytarabine, and melphalan) chemotherapy before allogeneic hematopoietic cell transplantation (alloHCT; transferring healthy cells from a donor) for relapsed or unresponsive lymphoma. This study concluded that alloHCT with BEAM chemotherapy is an alternative...

Read More

Evaluating the safety of EPOCH-R therapy for patients with non-Hodgkin’s lymphoma

Posted by on Jan 15, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated complications associated with reduced-intensity EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) therapy for patients with non-Hodgkin’s lymphoma (NHL). This study concluded that this treatment was associated with high rates of drug delivery complications. Some background...

Read More

Evaluating front-line allogeneic stem cell transplantation for mantle cell lymphoma

Posted by on Jan 12, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of patients with mantle cell lymphoma (MCL) after front-line (primary) allogeneic stem cell transplantation (alloSCT). This study concluded that front-line alloSCT is effective in these patients. Some background Chemoimmunotherapy containing rituximab (Rituxan) is the typical front-line...

Read More

Evaluating second-line rituximab-bendamustine treatment for patients with follicular lymphoma

Posted by on Jan 12, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of the BR (bendamustine, rituximab) regimen as a second-line treatment for patients with follicular lymphoma (FL) who had disease progression (tumor growth or spread) after chemoimmunotherapy. The study concluded that this regimen was effective in these patients. Some background...

Read More

Evaluating the long-term outcomes of Zevalin for patients with advanced B cell lymphoma

Posted by on Jan 10, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of patients with advanced (stage 3 – 4) non-Hodgkin’s lymphoma (NHL) who received radioimmunotherapy before allogeneic stem cell transplantation (alloSCT). This study concluded that this treatment regimen improved survival in most of these patients. Some background AlloSCT involves...

Read More

Safety and effectiveness of the biosimilar CT-P10 compared to rituximab in patients with follicular lymphoma

Posted by on Jan 3, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the safety and effectiveness of CT-P10 (Truxima) compared to rituximab (Rituxan) in the treatment of follicular lymphoma. Researchers found that CT-P10 had similar safety and effectiveness as rituximab in these patients. Some background Lymphoma is a cancer of the immune system. It is often treated with drugs...

Read More

Risk of hepatitis B reactivation in patients with lymphomas receiving obinutuzumab or rituximab

Posted by on Jan 3, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the risk of reactivating hepatitis B (HBV) infection in patients with lymphoma treated with obinutuzumab (Gazyva) or rituximab (Rituxan). Researchers found that HBV infection was reactivated in some of these patients but treatment options are available. Some background Lymphoma is a cancer of the immune system....

Read More

Does PET/CT scanning affect treatment and survival of patients with lymphoma?

Posted by on Dec 30, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the effect of PET/CT scanning on the treatment and survival of patients with lymphoma. Researchers found that PET/CT improved the management plan and survival of these patients. Some background PET/CT are types of scans that detect changes in cells and tissues inside the body. They can be used to check the sites of...

Read More

Is rituximab treatment effective in patients with aggressive B-cell lymphoma who are overweight?

Posted by on Dec 30, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the effectiveness of rituximab (Rituxan)-containing chemotherapy in the treatment of patients with B-cell lymphoma who are overweight. Researchers found that overweight patients treated with rituximab-containing treatment have improved outcomes. Some background B-cell lymphoma is a cancer of the immune system....

Read More

Evaluating the safety and effectiveness of axicabtagene ciloleucel for unresponsive B-cell lymphoma

Posted by on Dec 30, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the safety and effectiveness of axicabtagene ciloleucel (AC; Yescarta) in the treatment of unresponsive B-cell lymphoma. Researchers found that AC is a safe and effective treatment for these patients. Some background B-cell lymphoma is a cancer of cells in the immune system. It is treated with medication that targets...

Read More

Evaluating the impact of early PET/CT scanning on survival in patients with lymphoma after stem cell transplant

Posted by on Dec 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the impact of early FDG PET/CT scanning on the survival of patients with lymphoma after allogeneic stem cell transplantation (alloSCT). This study concluded that having positive scan results at 3 months after alloSCT may highly predict relapse and poor survival in these patients. Some background An alloSCT is a...

Read More